Trials / Completed
CompletedNCT02514603
A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers
A Phase 1 Study of LY2606368 in Japanese Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to assess the tolerability of prexasertib in Japanese participants with advanced solid cancers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prexasertib | Administered IV |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2017-04-10
- Completion
- 2017-04-10
- First posted
- 2015-08-03
- Last updated
- 2017-05-22
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02514603. Inclusion in this directory is not an endorsement.